Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Goodkin, D. E.
Right arrow Articles by Mocci, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goodkin, D. E.
Right arrow Articles by Mocci, S.
Neurology 2000;54:1414-1420
© 2000 American Academy of Neurology
Articles

A phase I trial of solubilized DR2:MBP84-102 (AG284) in multiple sclerosis

D. E. Goodkin, MD, M. Shulman, MD, J. Winkelhake, PhD, E. Waubant, MD, P.-B. Andersson, MD, PhD, T. Stewart, RN, S. Nelson, Dr.rer.nat, N. Fischbein, MD, P. K. Coyle, MD, E. Frohman, MD, L. Jacobs, MD, J. Holcenberg, MD, M. Lee, PhD and S. Mocci, MD, PhD

From the University of California at San Francisco/Mt. Zion Multiple Sclerosis Center (Drs. Goodkin, Waubant, Andersson, and Stewart); Anergen, Inc. (Drs. Shulman, Winkelhake, Holcenberg, and Mocci) Redwood City; the Department of Radiology (Drs. Nelson and Fischbein), University of California at San Francisco, CA; the State University of New York at Stony Brook (Dr. Coyle); University of Texas Southwestern Medical Center (Dr. Frohman), Dallas, TX; the State University of New York at Buffalo (Dr. Jacobs); and the International Quantitative Consultants, Inc. (Dr. Lee), North Hollywood, CA.

Address correspondence and reprint requests to Dr. Donald E. Goodkin, UCSF/Mt. Zion Multiple Sclerosis Center, 1701 Divisadero Street, Suite 480, San Francisco, CA 94115-1610.

OBJECTIVE: To assess the safety, tolerability, and biologic and clinical activity of a solubilized complex comprised of human leukocyte antigen—DR2 with myelin basic protein84-102 (AG284)in patients with secondary progressive MS.

BACKGROUND: Soluble species-specific major histocompatibility complex myelin basic protein91-103 complexes ameliorate disease in a dose-dependent manner when administered to SJL/J mice with chronic relapsing experimental allergic encephalomyelitis. Preincubation with AG284 reduces the proliferative response of a DR2-restricted, myelin basic protein84-102–reactive T cell clone, derived from a MS patient, to myelin basic protein84-102 in the presence of autologous antigen-presenting cells.

METHODS: Thirty-three patients with secondary progressive MS were randomly assigned to receive three alternate day IV doses of AG284 or placebo in a double-masked dose escalation study. The primary outcome was safety and tolerability. Secondary outcomes included a comparison of pre- and post-treatment gadolinium-enhanced brain MRI activity, Kurtzke Expanded Disability Status Scale, and Nine Hole Peg Test scores.

RESULTS: The frequency of adverse events was similar in the AG284 and placebo recipients. No significant treatment effect was detected by Expanded Disability Status Scale, Nine Hole Peg Test, or number of new gadolinium-enhancing MRI lesions.

CONCLUSIONS: AG284 as administered during this study was safe and well tolerated. Further studies are warranted to determine the biologic activity and clinical efficacy of this potential treatment for MS.

Key words: MS—Clinical trials—AG284—Anergy—Myelin






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by AAN Enterprises, Inc.